Literature DB >> 3986085

The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndrome.

M Ehsanullah, D A Lee, T Williams, P Pollard, B Gazzard.   

Abstract

The effect of oral secoverine hydrochloride on neostigmine-stimulated sigmoid motility in 12 patients with irritable bowel syndrome was studied in a double-blind placebo-controlled cross-over study. Both spontaneous and stimulated motor activity were significantly reduced by the compound in comparison with placebo. The most sensitive indices were the frequency of wave activity, maximum amplitude and motility index. Two patients reported mild dizziness after secoverine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3986085      PMCID: PMC1463735          DOI: 10.1111/j.1365-2125.1985.tb02647.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Drug usage in the irritable colon syndrome.

Authors:  K Goulston
Journal:  Med J Aust       Date:  1972-05-27       Impact factor: 7.738

2.  The effect of stimulation on the myoelectrical activity of the rectosigmoid in man.

Authors:  I Taylor; H L Duthie; R Smallwood; B H Brown; D Linkens
Journal:  Gut       Date:  1974-08       Impact factor: 23.059

3.  Observations on the mechanism of abdominal pain.

Authors:  D J Holdstock; J J Misiewicz; S L Waller
Journal:  Gut       Date:  1969-01       Impact factor: 23.059

Review 4.  The nervous system of the gut.

Authors:  M D Gershon; S M Erde
Journal:  Gastroenterology       Date:  1981-06       Impact factor: 22.682

5.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

6.  Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 2: General pharmacological properties.

Authors:  J M Zwagemakers; V Claassen
Journal:  Arzneimittelforschung       Date:  1980

7.  Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 1: Antimuscarinic and spasmolytic effects.

Authors:  J M Zwagemakers; V Claassen
Journal:  Arzneimittelforschung       Date:  1980

8.  Towards positive diagnosis of the irritable bowel.

Authors:  A P Manning; W G Thompson; K W Heaton; A F Morris
Journal:  Br Med J       Date:  1978-09-02

9.  Colonic myoelectrical activity in irritable-bowel syndrome. Effect of eating and anticholinergics.

Authors:  M A Sullivan; S Cohen; W J Snape
Journal:  N Engl J Med       Date:  1978-04-20       Impact factor: 91.245

10.  Site of pain from the irritable bowel.

Authors:  E T Swarbrick; J E Hegarty; L Bat; C B Williams; A M Dawson
Journal:  Lancet       Date:  1980-08-30       Impact factor: 79.321

View more
  3 in total

1.  Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome.

Authors:  G A Lanfranchi; G Bazzocchi; M Campieri; C Brignola; F Fois; B P Imbimbo
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Effect of secoverine on colonic myoelectric activity in diverticular disease of the colon.

Authors:  M Suchowiecky; D D Clarke; M Bhasker; R J Perry; W J Snape
Journal:  Dig Dis Sci       Date:  1987-08       Impact factor: 3.199

Review 3.  Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.

Authors:  Lisa Ruepert; A Otto Quartero; Niek J de Wit; Geert J van der Heijden; Gregory Rubin; Jean Wm Muris
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.